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METHODOLOGY ARTICLE
Nebulized heparin for patients 
under mechanical ventilation: an individual 
patient data meta-analysis
Gerie J. Glas1*, Ary Serpa Neto2,3,4, Janneke Horn1, Amalia Cochran5, Barry Dixon6, Elamin M. Elamin7, 
Iris Faraklas5, Sharmila Dissanaike8, Andrew C. Miller9,10 and Marcus J. Schultz1
Abstract 
Pulmonary coagulopathy is a characteristic feature of lung injury including ventilator-induced lung injury. The aim of 
this individual patient data meta-analysis is to assess the effects of nebulized anticoagulants on outcome of venti-
lated intensive care unit (ICU) patients. A systematic search of PubMed (1966–2014), Scopus, EMBASE, and Web of 
Science was conducted to identify relevant publications. Studies evaluating nebulization of anticoagulants in venti-
lated patients were screened for inclusion, and corresponding authors of included studies were contacted to provide 
individual patient data. The primary endpoint was the number of ventilator-free days and alive at day 28. Secondary 
endpoints included hospital mortality, ICU- and hospital-free days at day 28, and lung injury scores at day seven. We 
constructed a propensity score-matched cohort for comparisons between patients treated with nebulized antico-
agulants and controls. Data from five studies (one randomized controlled trial, one open label study, and three studies 
using historical controls) were included in the meta-analysis, compassing 286 patients. In all studies unfractionated 
heparin was used as anticoagulant. The number of ventilator-free days and alive at day 28 was higher in patients 
treated with nebulized heparin compared to patients in the control group (14 [IQR 0–23] vs. 6 [IQR 0–22]), though 
the difference did not reach statistical significance (P = 0.459). The number of ICU-free days and alive at day 28 was 
significantly higher, and the lung injury scores at day seven were significantly lower in patients treated with nebulized 
heparin. In the propensity score-matched analysis, there were no differences in any of the endpoints. This individual 
patient data meta-analysis provides no convincing evidence for benefit of heparin nebulization in intubated and 
ventilated ICU patients. The small patient numbers and methodological shortcomings of included studies underline 
the need for high-quality well-powered randomized controlled trials.
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Background
Pulmonary coagulopathy is a characteristic feature of var-
ious forms of lung injury, including acute respiratory dis-
tress syndrome (ARDS) [1–4], pneumonia [1, 5, 6], and 
inhalation trauma [7]. Recently, it was even demonstrated 
that mechanical ventilation has the potential to alter 
the pulmonary hemostatic balance [8], with remarkably 
similar changes in coagulation and fibrinolysis as found 
in ARDS, pneumonia, or inhalation trauma [1, 4, 7, 9].
Fibrin deposition and hyaline membrane formation 
are considered important early features in diffuse alveo-
lar damage, the hallmark of ARDS [1, 10–12]. Pulmonary 
activation of coagulation is likely to be involved in con-
taining inflammation or infection to the site of injury and 
may have evolved as a host-protective mechanism [13, 14]. 
However, these local hemostatic disturbances could also 
be deleterious, as excessive or persistent fibrin deposition 
has been associated with alveolar collapse due to impaired 
surfactant function [15], pulmonary edema and impaired 
gas exchange [16], and eventually pulmonary fibrosis [17].
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While preclinical studies provided support for the 
use of nebulized or systemic anticoagulants to prevent 
lung injury in animals [18, 19], clinical studies in venti-
lated patients thus far showed conflicting results [19, 
20]. Clinical trials have been performed in patients with 
(mild) ARDS or sepsis, focusing on systemic treatment 
with anticoagulants such as recombinant human (rh)-
activated protein C, antithrombin, rh-tissue factor path-
way inhibitor, and unfractionated heparin. All but one 
trial were unsuccessful in improving patient outcomes 
[21–32]. It has been suggested that higher concentrations 
of an anticoagulant in the pulmonary compartment may 
be necessary to affect pulmonary disturbances [19]. Thus, 
local administration of anticoagulants to the pulmonary 
compartment could be considered a more effective anti-
coagulant intervention.
Over the last decades, nebulized heparin has been 
safely administered in a number of pulmonary conditions 
[33–35]. Studies in healthy volunteers showed nebu-
lized heparin to reach the lower respiratory tract [36], 
distribute uniformly in the lungs [36], and exert local 
anticoagulant effects [35]. In line herewith, nebulized 
heparin attenuated pulmonary coagulopathy in critically 
ill patients with acute lung injury [37]. Intrapulmonary 
administered heparin crosses the alveolar membrane 
into the circulation, being absorbed rapidly and released 
gradually into the blood [38]. Indeed, there is evidence 
of a dose-dependent effect of heparin nebulization on 
plasma levels of aPTT [35, 39], with a threshold dose of 
150,000 IU of heparin resulting in a measurable increase 
in aPTT [35]. This effect on systemic coagulation does 
not seem to potentiate the risk of bleedings [39–41], 
suggesting heparin nebulizations to be safe. Neverthe-
less, data on the feasibility and safety of heparin nebuli-
zations in ventilated patients are scarce [19], and there 
are very limited data on the use of nebulized anticoagu-
lants in ventilated patients. A systematic review recently 
showed conflicting effects of nebulized anticoagulation 
in burn patients with inhalation injury, a patient popula-
tion in which this intervention is frequently applied [20]. 
It remains unclear whether nebulized anticoagulation 
is beneficial for all ventilated intensive care unit (ICU) 
patients. We performed an individual patient data meta-
analysis to determine the association between nebulized 
anticoagulants and outcomes of intubated and ventilated 
ICU patients to test the hypothesis that nebulization of 
anticoagulants improves outcome.
Methods
Systematic search
Publications were identified through a systematic 
search of PubMed (1966–2014), Scopus, EMBASE, 
and Web of Science. Search terms referred to the 
intervention (nebulized, vaporized, aerosolized) and 
anticoagulant agents (anticoagulants, anticoagulation, 
antithrombins, heparin), as well as conditions of the 
patient population (acute lung injury, ARDS, critical 
illness, burn, smoke, inhalation injury) and mechanical 
ventilation. Searches were not limited by date or lan-
guage. The detailed search strategy is shown in Addi-
tional file 1: Appendix 1.
Titles and available abstracts of the articles identi-
fied were screened. Studies were eligible for inclusion if 
they evaluated nebulized or aerosolized anticoagulants, 
including heparins, heparinoids, antithrombins, and/or 
fibrinolytics, in ventilated ICU patients. There were no 
restrictions regarding age of patients. Case reports and 
ongoing studies were excluded. Retrieved articles were 
screened for pertinent information, and reference lists of 
eligible articles were screened for potentially important 
papers. Quality of evidence for randomized and nonran-
domized studies were assessed with use of, respectively, 
the Cochrane Collaboration’s tool for assessing risk of 
bias [42] and the Newcastle Ottawa Scale [43], see Addi-
tional file 1: Appendix 5.
Collection of individual patient data
The corresponding author of each included study was 
contacted and asked for individual patient data. This 
included demographic and baseline characteristics, dose 
and duration of nebulized anticoagulants, duration of 
ventilation, occurrence of pneumonia, length of stay in 
the ICU and hospital, and mortality. Ventilatory param-
eters and lung injury scores (LIS) [44] were collected up 
to 7 days from admission. Data were accepted in any kind 
of electronic format.
Primary outcome
The primary outcome was the number of ventilator-free 
days and alive at day 28, defined as the number of days 
alive and without ventilation until day 28.
Secondary outcomes
Secondary outcomes included mortality during hospital 
stay, ICU-free days at day 28, defined as the number alive 
and outside the ICU at day 28, and hospital-free days 
and alive at day 28, defined as the number of days alive 
and outside hospital at day 28. PaO2/FiO2 and LIS at day 
seven, calculated from the available data, and occurrence 
of pneumonia during hospital stay.
Statistical analysis
Continuous variables were presented as median and 
interquartile range (median [IQR]). Binary and categori-
cal variables were presented as frequencies and percent-
ages [n (%)].
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Patients were analyzed according to use or not of nebu-
lized anticoagulants. Time-to-event was defined as time 
from the day of inclusion in the study to the event of 
interest. We used a Cox proportional-hazards regression 
model to examine simultaneous effects of multiple covar-
iates on outcomes, censoring patient data at the time of 
death, or hospital discharge. In all models, the categorical 
variables were tested for trend with the nonuse of nebu-
lized anticoagulants as reference. The proportional-haz-
ards assumption was assessed plotting partial residuals 
against survival time. A test for interaction between pairs 
of variables in the final model was performed. The effect 
of each variable in these models was assessed with the use 
of the Wald test and described by the hazard ratio with 
95 % confidence interval (CI). The initial model included 
age and baseline PaO2/FiO2. The final model was devel-
oped by dropping each variable in turn from the model 
and by conducting likelihood-ratio tests to compare the 
full and the nested models. We used a significance level 
of 0.05 as the cutoff to exclude a variable from the model. 
Finally, use of nebulized anticoagulants (no vs. yes) was 
added to the model. Kaplan–Meier curves and log-rank 
test were used to determine the univariate significance of 
the study variables.
A linear mixed model was used to analyze time-course 
variables. A repeated-measures generalized linear model 
(GLM) was used to assess the time interaction for ven-
tilatory and oxygenation parameters during mechanical 
ventilation. The model includes two factors: (1) study 
group (fixed factor), each level of the study group factor 
had a different linear effect on the value of the dependent 
variable; (2) time as covariate, time was considered to be 
a random sample from a larger population of values, and 
the effect was not limited to the chosen times.
Subgroup analyses were used to assess the effect of 
tidal volume size in the following prespecified subgroups: 
(1) age (<18 vs. ≥18 years); (2) dose of nebulized antico-
agulant (low dose, defined as 30,000 U/day versus high 
dose, defined as ≥60,000 U/day); and (3) patient popu-
lation (burn vs. non-burn). Propensity scores were esti-
mated for each patient with logistic regression using two 
clinically relevant baseline characteristics (age and base-
line PaO2/FiO2). Propensity score matching is described 
in detail in the supplemental material (Appendix file 1: 
Appendix 4). We conducted a post hoc sensitivity analysis 
in the matched cohort, including age (<18 vs. ≥18 years), 
dose of nebulized anticoagulant (low dose, defined as 
30,000  U/day vs. high dose, defined as 60,000  U/day or 
higher), patient population (burn vs. non-burn), and tidal 
volume size (low, defined as ≤560 ml vs. high, defined as 
>560 ml by using the median as a cutoff value). All analy-
ses were conducted with Review Manager v.5.1.1 (The 
Nordic Cochrane Centre, The Cochrane Collaboration, 
Copenhagen, Denmark), SPSS v.20 (IBM Corporation, 
New York, USA), and R v.2.12.0 (R Foundation for Statis-
tical Computing, Vienna, Austria). For all analyses two-
sided P values <0.05 were considered significant.
Results
Systematic search
The search yielded 216 potentially relevant publications 
(Fig. 1). Based on the titles or abstracts, 202 publications 
were excluded. The remaining 14 publications reported 
on ten clinical studies, all on nebulized heparin [39–41, 
45–55]. One publication reported on an ongoing trial 
[49]. Nine studies were eligible for inclusion in our indi-
vidual patient data meta-analysis (521 patients). How-
ever, the corresponding authors of three studies did not 
provide the individual patient data [41, 45, 48], and one 
could not be contacted [53]. Therefore, data from five 
studies (286 patients) were available for the meta-analysis 
[39, 40, 50–52].
Table  1 summarizes the study characteristics of the 
included studies. All three studies conducted in burn 
patients with inhalation injury were retrospective stud-
ies with historical controls [50–52]. One open label 
phase I study and one randomized controlled trial were 
conducted in critically ill patients [39, 40]. One study 
had a mixed population with both pediatric and adult 
patients [50], and all other studies were performed in 
adult patients. Dosage of heparin varied from 30,000 to 
400,000 U/day.
Of note, patients treated with nebulized heparin were 
ventilated with lower tidal volumes during the first 7 days 
of ventilation (Additional file  1: Appendix 3: Tables S1 
Fig. 1 Prisma flow diagram showing the literature search and selec-
tion strategy
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and Appendix 4: Table S5). All other ventilatory param-
eters were similar between the two study groups (Addi-
tional file 1: Appendix 2: Figures S2 and S3; Appendix 3: 
Table S1).
Table  2 summarizes the demographic data of the 
included patients. For the propensity score-matched 
cohort, 248 patients could be analyzed (Additional file 1: 
Appendix 4: Table S3).
Effects of heparin on outcome
The median number of ventilator-free days and alive 
at day 28 did not differ in patients treated with nebu-
lized heparin compared to patients in the control group 
(14, IQR 0–23 vs. 6, IQR 0–22 days, P = 0.459). A sta-
tistically significant difference was found for ICU-free 
days at day 28 (3 [0–19] vs. 0 [0–14] days, P =  0.035). 
The LIS at day seven were also significantly lower in 
patients treated with nebulized heparin (2.0 [1.0–2.5] 
vs. 2.2 [1.7–3.0] days, P =  0.027). There was no differ-
ence in hospital mortality (Table 3 and Additional file 1: 
Appendix 2: Figure S1), hospital-free days and alive at 
day 28 or occurrence of pneumonia during hospital stay 
(Table 3).
In subgroup analyses, there was no difference in num-
ber of ventilator-free days at day 28, overall mortality nor 
number of hospital-free days and alive at day 28, accord-
ing to age (<18 vs. ≥18  years), dose of heparin, type of 
population and tidal volume size (Additional file  1: 
Appendix 3: Table S2).
Propensity score‑matched cohort
Results of the meta-analysis in the propensity score-
matched cohort are presented in the online supplement 
(Additional file 1: Appendix 4: Tables S3–S6).
The median number of ventilator-free days at day 28 in 
patients treated with nebulized heparin was higher than 
that in control patients (16 [0–23] vs. 5 [0–20] days), but 
again this difference did not reach statistical significance 
(P = 0.133). Also, no statistical differences were found for 
the number of ICU-free days and alive at day 28 and LIS 
at day seven and other secondary endpoints (Additional 
file 1: Appendix 2: Figure S1 and Appendix 4: Table S4).
Also in this part of the analysis, it was found that 
patients treated with nebulized heparin were ventilated 
with lower tidal volumes than control patients during the 
first 7 days of ventilation (Additional file 1: Appendix 4: 
Table S5). In the post hoc sensitivity analysis on age, dose 
of heparin, type of population and tidal volume size, no 
differences were found for ventilator-free days and hos-
pital-free days at day 28 (Additional file  1: Appendix 4: 
Table S6).
Discussion
Nebulization of heparin, alone or combined with other 
agents, did not improve the outcome of mechanically 
ventilated patients in this individual patient data meta-
analysis. Even though patients who received nebuli-
zation with heparin demonstrated higher numbers 
of ventilator-free days and alive at day 28, differences 
Table 1 Characteristics of studies included in the individual patient data meta-analysis
VFD-28 ventilator-free days and alive at day 28, IPD individual patient data meta-analysis, LIS Lung injury scores
Authors 
(year)
Design Population (adult/pedi‑
atric)
Number 
of patients
Dose of heparin Outcomes included 
in IPD meta‑analysis
References
Heparin Control
Holt 
(2008)
Retrospective with histori-
cal control
Smoke inhalation (adult 
and pediatric)
62 88 30,000 VFD-28; hospital mortality; 
pneumonia; PaO2/FiO2 at 
day 7; hospital-free days 
and alive at day 28
[50]
Dixon 
(2008)
Open label phase 1 trial Critically ill (adult) 16 – 50,000–400,000 VFD-28; ICU mortality; ICU 
and hospital-free days 
and alive at day 28
[39]
Miller 
(2009)
Retrospective with histori-
cal control
Smoke inhalation (adult) 16 14 60,000 VFD-28; hospital mortality; 
PaO2/FiO2 and LIS at day 
7; ICU and hospital-free 
days and alive at day 28; 
pneumonia
[52]
Dixon 
(2010)
Randomized controlled trial Critically ill (adult) 25 25 150,000 VFD-28; hospital mortality; 
PaO2/FiO2 and LIS at day 
7; ICU and hospital-free 
days and alive at day 28
[40]
Kashefi 
(2014)
Retrospective with histori-
cal control
Smoke inhalation (adult) 20 20 30,000 VFD-28; hospital mortality; 
pneumonia; PaO2/FiO2; 
and hospital-free days 
and alive at day 28
[51]
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were not statistically significant. We did find a higher 
number of ICU-free days and alive at day 28 and lower 
LIS at day seven in patients treated with nebulized 
heparin. A propensity score-matched cohort analy-
sis, however, showed no beneficial effects of heparin 
nebulization.
Table 2 Characteristics of the patients included in the individual patient data analysis
Values are median (IQR) or no./total no. (%). Not all requested data were available for each study
SD standardized difference, TBSA total burn surface area, NAC N-acetylcysteine, LIS lung injury scores, N number of patients
Variables Overall cohort (N = 286)
Nebulized heparin (N = 139) Control (N = 147) SD (%), P
Age, years 50.0 (36.0–69.0) 45.0 (31.0–63.0) 17.6, 0.09
(N = 139) (N = 147)
Gender, male (%) 81 (65.9) 107 (72.8) −19.0, 0.14
APACHE III 22.0 (17.0–31.0) 24.0 (15.0–32.0) 5.1, 0.74
(N = 57) (N = 39)
% TBSA 25.5 (12.9–52.2) 31.2 (16.5–52.2) −5.1, 0.51
(N = 90) (N = 110)
Dosage of heparin (U/day) 30,000 0.0 –
(30,000–100,000) (0.0–0.0)
Dosage of NAC (mg/day) 3600 (3600–3600) 0.0 (0.0–0.0) –
Duration of treatment 7.0 (3.0–12.0) 0.0 (0.0–0.0) –
Baseline LIS 2.0 (0.7–2.5) 2.0 (1.2–3.0) −26.2, 0.29
(N = 41) (N = 39)
Baseline PaO2/FiO2 219.5 (158.2–316.5) 270.0 (163.5–366.5) −18.3, 0.09
(N = 136) (N = 141)
Table 3 Primary and secondary outcomes
Values are median (IQR), and others are no./total no. (%)
Not all requested data were available for each study
LIS lung injury scores, CI confidence interval, N number of patients
a Adjusted by: age and baseline PaO2/FiO2
b Presented as hazard ratio adjusted by: age, %TBSA, and baseline PaO2/FiO2
Variables Nebulized heparin (N = 139) Control (N = 147) Odds ratioa (95 % CI) P
Primary outcome
Ventilator-free days at day 28 14.0 (0.0–23.0) 6.0 (0.0–22.0) 0.459
(N = 139) (N = 144)
Secondary outcomes
Overall mortality 34/139 (24.5) 35/147 (23.8) 0.65 (0.50–1.56)b 0.653
(N = 139) (N = 147)
PaO2/FiO2 at day seven (mmHg) 242.5 (206.0–300.0) 220.2 (179.4–297.7) 0.098
(N = 61) (N = 78)
LIS at day seven 2.0 (1.0–2.5) 2.2 (1.7–3.0) 0.027
(N = 40) (N = 48)
Pneumonia during hospital stay 48/82 (58.5) 48/106 (45.3) 1.49 (0.79–2.80) 0.219
(N = 82) (N = 106)
ICU-free days at day 28 2.9 (0.0–19.0) 0.0 (0.0–14.2) 0.035
(N = 78) (N = 62)
Hospital-free days at day 28 0.0 (0.0–12.0) 0.0 (0.0–14.0) 0.951
(N = 139) (N = 147)
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The aim of this individual patient data meta-analysis 
was to investigate the effectiveness of nebulized anti-
coagulants in intubated and ventilated ICU patients. 
Since heparin was the only anticoagulant agent used 
in the included studies, we are unable to ascertain the 
potential efficacy of any other anticoagulant, due to pau-
city of available evidence. Also, the majority of patients 
included were patients with inhalation injury (220 of 
286). Thus, conclusions on the effects of nebulized hepa-
rin for intubated and ventilated ICU patients in general 
cannot be made. As adverse effects of mechanical venti-
lation may be more severe in burn patients, it is possible 
that these patients benefit more from nebulized anti-
coagulants compared to non-burn or smoke inhalation 
patients [19].
Reported effects of nebulized heparin on duration of 
mechanical ventilation and other outcomes such as mor-
tality in patients with inhalation injury have been con-
flicting. Beneficial effects of heparin nebulization could 
have been confounded by improvements in ICU care in 
general as they were conducted around a change in insti-
tutional protocol [45, 52]. In two other before–after stud-
ies no beneficial effects of heparin nebulizations were 
seen [50, 51]. Furthermore, in three of the included stud-
ies [50–52], nebulized heparin was combined with the 
use of mucolytic agents and bronchodilators. This high-
lights the difficulty to distinguish between the effects of 
heparin nebulization and other parts of treatment on 
patient outcome in retrospective studies with historical 
controls.
One important finding of our individual patient data 
meta-analysis was that patients receiving heparin nebu-
lization were ventilated with lower tidal volumes com-
pared to control patients. While in theory improved 
clinical outcomes could have been caused by nebuliza-
tion of heparin, it could also function as an important 
confounder, since low tidal volume ventilation is asso-
ciated with a better outcome, also in patients without 
ARDS [56–60]. Still, relatively high tidal volumes were 
used in all included studies which may hamper extrapola-
tion to current ventilation practices. On the other hand, 
while lower tidal volumes are increasingly being used [61, 
62], guidelines inconsistently advise on tidal volume size 
in ICU patients without ARDS and current ventilation 
practice is uncertain [63].
Dosage of heparin varied from 30,000 to 400,000 U/
day. Several studies suggested a dose-dependent effect 
of heparin nebulization in which dosages of 30,000 U/
day improved outcomes in pediatric patients [45] but 
failed to improve outcomes in adults [50, 51], while 
higher dosages did improve outcome of adult patients 
[48, 52]. The present meta-analysis could not con-
firm this. Types of nebulizers and its position in the 
circuit may affect the delivery of nebulized drugs in 
ventilated patients [64–66]. Furthermore, aerosol par-
ticle size distribution and heparin concentrations may 
also influence the amount of heparin delivered to the 
lower respiratory tract [67]. The method of nebuliza-
tion differed between studies. Three studies used mesh 
nebulizers [39, 40, 50], and two studies used jet nebu-
lizers [51, 52]. Thus, the delivered amount of nebulized 
drugs may have varied.
Our results contradict the conclusion of a previous sys-
tematic review concluding that inhaled anticoagulation 
regimens improve survival and decrease morbidity in 
smoke inhalation patients [20]. This may be due to some 
major differences between the two studies. First, as our 
aim was to investigate the effect of heparin nebulization 
in any critically ill patient, we included different studies. 
Second, the use of individual patient data allowed stand-
ardization of the analyses across studies irrespective of 
how the data were reported [68].
One major limitation of this meta-analysis is that 
we were only able to analyze the individual data of 286 
patients out of 521 potentially eligible patients as the 
authors of four studies did not provide individual patient 
data. Other limitations are caused by the methodologi-
cal shortcomings of included studies. Only one of the 
included studies was a small, but properly conducted ran-
domized controlled trial [40]. The other studies, mostly 
small in size, used an open label design or were retro-
spective cohort studies with use of historical controls. 
Due to these limitations, the results from this meta-anal-
ysis should be interpreted with great caution. To account 
for some of those limitations we used propensity score 
matching correcting for relevant baseline characteristics. 
However, imbalances such as the presence of unmeas-
ured confounders are likely to remain [69]. Nevertheless, 
the post hoc sensitivity analysis indicates that the results 
of this meta-analysis were affected neither by factors 
such as age, presence of burn, or inhalation injury nor by 
differences in tidal volume size and heparin dosages.
Conclusion
No beneficial effects of heparin nebulization on the out-
come of ventilated patients were observed in this indi-
vidual patient data meta-analysis. The small patient 
numbers and methodological shortcomings of included 
studies underline the need for high-quality well-powered 
randomized controlled trials to determine the effect of 
heparin nebulization on outcome of intubated and venti-
lated ICU patients.
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